Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes-Reference-Cited by-同舟云学术

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Published:2016-07 Issue:7 Volume:27 Page:1317-1323
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cheah C.Y.,Chihara D.,Horowitz S.,Sevin A.,Oki Y.,Zhou S.,Fowler N.H.,Romaguera J.E.,Turturro F.,Hagemeister F.B.,Fayad L.E.,Wang M.,Neelapu S.S.,Nastoupil L.J.,Westin J.R.,Rodriguez M.A.,Samaniego F.,Anderlini P.,Nieto Y.,Fanale M.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/7/1317/6679011/mdw169.pdf

Reference23 articles.

1. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma;Connors;Blood,2015

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

4. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

5. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804;Bartlett;Ann Oncol,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions;Clinical Pharmacology & Therapeutics;2023-06-09

2. Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls;Clinical Pharmacology & Therapeutics;2023-06-09

3. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies;Hematology;2023-03-09

4. Real-World Data in Health Technology Assessment: Do We Know It Well Enough?;Human Perspectives in Health Sciences and Technology;2022

5. Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy;AboutOpen;2021-09-02